Research material and lot documents
Tesamorelin for sale as research material is a different thing from Egrifta, the FDA-approved prescription drug that contains tesamorelin. The FDA label and approval records describe Egrifta products, not research vials. Curo's research catalog, which lists Tesamorelin 20mg, shows one such listing.
A research listing usually gives a compound name, a label amount per vial and a lot number. Those are the supplier's statements. A lot report is the separate document that records measurements for that lot. Neither document is an FDA approval, and the approval records on tesamorelin FDA approval records name only the Egrifta products.
Curo's testing page lists what each report covers: identity by FTIR or LC-MS, purity by HPLC as a percentage of peak area, fill as the measured amount per vial, and endotoxin and sterility where available. The same page says each report is tied to the lot number on the vial.
These steps follow the "Reading a COA" list on the same testing page.
Find the lot number printed on the vial label.
Enter that exact lot number in Curo's COA library.
Confirm that the compound and fill on the report match the vial label.
Review the identity, purity, fill and endotoxin results.
The Egrifta label gives the molecular formula of tesamorelin acetate and a free-base molecular weight of 5135.9 Da. PubChem lists the free-base formula C221H366N72O67S under CID 16137828. An LC-MS identity result is a measured molecular mass, so a report's value can be read against that reference. The reference describes the compound. The report describes the lot. Sources: FDA label for Egrifta WR, revised March 2025 and PubChem tesamorelin record, CID 16137828.
Drugs@FDA lists Egrifta under BLA 022505 with the applicant Theratechnologies. No FDA record read for this site lists a research material. Curo's research-use policy states that its products are designated research use only and that its statements have not been evaluated by FDA. Source: Drugs@FDA record for BLA 022505.
The identity and trial record is on the tesamorelin peptide identity and research record. The comparisons are on tesamorelin vs sermorelin and tesamorelin vs ipamorelin.